KALA BIO, Inc.

KALA

US4831192020

KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development and commercialization of therapies for rare and severe diseases of the eye. The Companyâs biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Companyâs product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived bio factors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its KPI-012 is used for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.

Sector

Pharmaceuticals

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.512 USD

Average target price

18.33 USD

Spread / Average Target

+181.55%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
KALA BIO, INC.	-6.98%	18.34M
ELI LILLY AND COMPANY	+38.51%	727B
NOVO NORDISK A/S	+33.05%	599B
JOHNSON & JOHNSON	-6.23%	354B
MERCK & CO., INC.	+18.78%	328B
ABBVIE INC.	+1.35%	277B
ASTRAZENECA PLC	+16.00%	243B
NOVARTIS AG	+8.09%	205B
ROCHE HOLDING AG	-5.77%	203B
AMGEN INC.	+6.19%	164B

Other Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:30:01 24/05/2024 BST			5-day change	1st Jan Change
6.512 ^USD	+0.18%		-0.59%	-6.98%

05-17	HC Wainwright Adjusts Kala Pharmaceuticals Price Target to $18 From $21, Maintains Buy Rating	MT
04-02	HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating	MT

HC Wainwright Adjusts Kala Pharmaceuticals Price Target to $18 From $21, Maintains Buy Rating	05-17	MT
HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating	04-02	MT
KALA BIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-29	CI
KALA BIO, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-29	CI
KALA BIO, Inc. announced that it expects to receive $8.599799 million in funding from Baker Bros. Advisors LP	03-24	CI
North American Morning Briefing : Stocks Struggle After New Records	03-22	DJ
North American Morning Briefing : Inflation -2-	03-15	DJ
KALA BIO, Inc. announced that it expects to receive $1.999824 million in funding	12-20	CI
HC Wainwright Adjusts Kala Pharmaceuticals Price Target to $22 From $24, Maintains Buy Rating	11-17	MT
Wedbush Lowers Kala Pharmaceuticals' PT to $22 From $39, Moves US Launch Estimate for Lead Asset KPI-012; Maintains Outperform Rating	11-14	MT
KALA BIO, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Wedbush Cuts Kala Pharmaceuticals' Price Target to $39 From $42, Maintains Outperform Rating	04/08/23	MT
KALA BIO, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	04/08/23	CI
Kala Pharmaceuticals Changes Name to Kala Bio	02/08/23	MT
Kala Pharmaceuticals, Inc. Announces Robert Paull Not Stands for Re-Election as A Director	11/05/23	CI
Kala Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	09/05/23	CI
Kala Pharmaceuticals Unit Secures $15 Million Grant from California Institute for Regenerative Medicine	28/04/23	MT
Kala Pharmaceuticals Shares Rise Nearly 5% After FDA Fast Track Designation	12/04/23	DJ
HC Wainwright & Co. Adjusts Price Target on Kala Pharmaceuticals to $22 From $20, Keeps Buy Rating	12/04/23	MT
Kala Pharmaceuticals, Inc. Appoints Francis Mah as Chief Medical Advisor	29/03/23	CI
Kala Pharmaceutical to Proceed with Corneal Epithelial Defect Trial After Positive Safety Data in Cohort 1	27/03/23	MT
Kala Pharmaceuticals, Inc. Announces Positive Safety Update from Cohort 1 of Chase Phase 2B Clinical Trial Evaluating KPI-012 in Patients with PCED	27/03/23	CI
Top Premarket Gainers	06/03/23	MT
HC Wainwright Adjusts Price Target on Kala Pharmaceuticals to $20 From $12, Keeps Buy Rating	06/03/23	MT
Wedbush Lowers Kala Pharmaceuticals' Price Target to $42 From $47 Due to Increased Share Count, Keeps Outperform Rating	06/03/23	MT

KALA BIO, Inc.

Equities